Antimicrobial resistance
The global community is currently facing the escalating challenge of antimicrobial resistance (AMR), which poses significant threats to human and animal health, food security, and global economic stability. AMR substantially complicates the treatment and prevention of infections, increases the risk of severe complications (particularly in vulnerable populations), leads to prolonged hospital stays, and raises overall healthcare costs. The high unmet need and urgency for action to address the burden of AMR is best articulated by the World Health Organization (WHO), which has declared AMR a global health emergency that will seriously jeopardize progress in modern medicine. The AMR crisis necessitates a coordinated, interdisciplinary approach to mitigate its far-reaching consequences.
Parexel brings comprehensive support in the development of novel antimicrobial products and diagnostics to address AMR. With strong medical expertise in AMR clinical trials, a patient-centric approach, up-to-date regulatory guidance, advanced feasibility services supported by real-world-evidence and first in class global operational footprint, Parexel enhances the clinical development process. By fostering partnerships, optimizing trial designs, and providing post-marketing support, Parexel accelerates the development and monitoring of urgently needed antimicrobial products and novel diagnostic tools. This multifaceted approach positions Parexel as a crucial partner in combating AMR, benefiting our patients and sponsors in the pursuit of innovative antimicrobial solutions.
Clinical trial experience
+
clinical trials with antibacterials, antivirals (including preventative vaccines), antifungals, or antiparasitic therapies in past 5 years
+
investigators supported AMR clinical trials in past 5 years
+